QNCX (Quince Therapeutics) Institutional Ownership: 7.25% (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

QNCX Quince Therapeutics Inc QNCX
24 GF Score
Price $34.57
! 2 Warning Signs
View Full Analysis

What is Quince Therapeutics Institutional Ownership?

Quince Therapeutics QNCX +4.41% 24 Institutional Ownership is 7.25% as of Aug. 20, 2026. GuruFocus rates QNCX with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Quince Therapeutics's institutional ownership is 7.25%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Quince Therapeutics's Insider Ownership is 15.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Quince Therapeutics's Float Percentage Of Total Shares Outstanding is 99.42%.

Quince Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Quince Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quince Therapeutics Institutional Ownership Chart

Quince Therapeutics Historical Data

The historical data trend for Quince Therapeutics can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 6.07 6.57 6.75 7.14 7.07 1.19 1.00 0.70 0.28 0.27
QNCX
24GF Score
Quince Therapeutics Inc QNCX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quince Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 7.25% mean?
Quince Therapeutics (QNCX) has a Institutional Ownership of 7.25% as of Aug. 20, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Quince Therapeutics and its competitors.
Is Quince Therapeutics' Institutional Ownership too high?
Quince Therapeutics' current Institutional Ownership is 7.25%. Overall, Quince Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Quince Therapeutics' Institutional Ownership compare to LPCN and NXTC?
Quince Therapeutics' Institutional Ownership of 7.25% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Quince Therapeutics and its competitors. Quince Therapeutics's current Institutional Ownership is 7.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quince Therapeutics stock overvalued right now?
Quince Therapeutics (QNCX) has a current Institutional Ownership of 7.25%. The current Institutional Ownership is 7.25%. Quince Therapeutics' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Quince Therapeutics (QNCX), the current Institutional Ownership is 7.25% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quince Therapeutics Business Description

Address 611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
24GF Score

Get the complete analysis for QNCX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.57
Price